Systemic and coronary hemodynamic effects of intracoronary administration of prostaglandins E1 and E2.
D000319:Adrenergic beta-Antagonists / Q000494:pharmacology; D000818:Animals; D001794:Blood Pressure / Q000187:drug effects; D006328:Cardiac Catheterization; D002302:Cardiac Output / Q000187:drug effects; D003326:Coronary Circulation / Q000187:drug effects; D003331:Coronary Vessels; D006439:Hemodynamics / Q000187:drug effects*; D007269:Injections, Intra-Arterial; D009206:Myocardium / Q000378:metabolism; D010101:Oxygen Consumption; D011433:Propranolol / Q000494:pharmacology; D011453:Prostaglandins / Q000008:administration & dosage / Q000494:pharmacology*; D013015:Sotalol / Q000494:pharmacology; D014655:Vascular Resistance / Q000187:drug effects; D014665:Vasodilator Agents
D000319:Adrenergic beta-Antagonists; D011453:Prostaglandins; D014665:Vasodilator Agents; D011433:Propranolol; D013015:Sotalol